Form D Flow: Luna Pharmaceuticals $3.50 million Fundraising. Peter Finn Published Nov 8 D Filing

Health Care Luna Pharmaceuticals, Inc. - Peter Finn

Luna Pharmaceuticals Financing

Luna Pharmaceuticals, Inc., Corporation just submitted form D because of $3.50 million equity financing. This is a new filing. Luna Pharmaceuticals was able to fundraise $1.82 million so far. That is 52.10% of the round of financing. The total private offering amount was $3.50 million. This form was filed on 2016-11-08. The reason for the financing was: Executive salaries.. The fundraising still has about $1.68 million more and is not closed yet. We have to wait more to see if the offering will be fully taken.

Luna Pharmaceuticals is based in Rhode Island. The firm’s business is Other Health Care. The D form was filed by Peter Finn Secretary. The company was incorporated more than five years ago. The filler’s address is: 244 Weybosset Street, 2Nd Floor, Suite 3, Providence, Ri, Rhode Island, 02903. Dan Aziz is the related person in the form and it has address: 244 Weybosset Street, 2Nd Floor, Suite 3, Providence, Ri, Rhode Island, 02903. Link to Luna Pharmaceuticals Filing: 000168848316000001.

Analysis of Luna Pharmaceuticals Offering

On average, companies in the Other Health Care sector, sell 68.60% of the total offering size. Luna Pharmaceuticals sold 52.10% of the offering. The fundraising is still open. The average offering amount for companies in the Other Health Care industry is $1.16 million. The total amount raised is 57.21% bigger than the average for companies in the Other Health Care sector. The minimum investment for this fundraising is set at $5000. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Luna Pharmaceuticals Also

The Form D signed by Peter Finn might help Luna Pharmaceuticals, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment